Interleukin 12 (IL-12) is increased in tumour bearing human liver and expands CD8+ and CD56+ T cells in vitro but not in vivo

Cytokine

Volumn 25, Issue 6, 2004, Pages 273-282

  Kelly, Anna M ^a   Golden Mason, Lucy ^a   McEntee, Gerry ^a   Traynor, Oscar ^a   Doherty, Derek G ^b   Hegarty, John E ^a,c   O'Farrelly, Cliona ^a,c  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cytokine; NKT; T lymphocytes; Tumour immunity

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2;

ARTICLE; BLOOD CELL; CELL ACTIVATION; CELL CULTURE; CELL INFILTRATION; CELL POLARITY; CELL TYPE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER TUMOR; MONOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; TH1 CELL;

MURINAE;

EID: 1242338971     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2003.11.012     Document Type: Article

References (38)

1. Taylor I. Liver metastases from colorectal cancer: lessons from past and present clinical studies. Br J Surg. 83:(4):1996;456-460.
2. Hata K., Ru Zhang X., Iwatsuki S., Van Thiel D., Heberman R., Whiteside T. Isolation, phenotyping and functional analysis of lymphocytes from human liver. Clin Immunol Pathol. 56:1990;401-419.
3. Norris S., Collins C., Doherty D.G., Smith F., McEntee G., Traynor O., et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol. 28:1998;84-90. 10.1016/S0168-8278(98)80206- 7.
4. Norris S., Doherty D.G., Collins C., McEntee G., Traynor O., Hegarty J., et al. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Vα24JαQ and γδ T cell receptor bearing cells. Hum Immunol. 60:1999;20-31. 10.1016/S0022-1759(00)00204-0.
5. Porgador A., Mandelboim O., Restifo N.P., Strominger J.L. Natural killer cell lines kill autologous Beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci U S A. 94:(24):1997;13140-13145.
6. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., et al. Characterisation of an antigen that is recognised on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 6:(2):1997;199-208.
7. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., et al. Differential tumour surveillance by Natural Killer (NK) and NKT cells. J Exp Med. 191:2000;661-668.
8. Smyth M.J., Crowe N.Y., Godfrey D.I. NK cells and NKT cells collaborate in host protection against methylcholanthrene-induced fibrosarcoma. Int Immunol. 13:2001;459-463.
9. Takeda K., Hayakawa Y., Atsuta M., Hong S., Van Kaer L., Kobayashi K., et al. Relative contribution of NK and NKT cells to the antimetastatic activities of IL-12. Int Immunol. 12:(6):2000;909-914.
10. Shin T., Nakuyama T., Akutsu Y., Motohashi S., Shibata Y., Harada M., et al. Inhibition of tumour metastases by adoptive transfer of IL-12 activated Valpha14 NKT cells. Int J Cancer. 91:(4):2001;523-528.
11. Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., et al. Requirement for Vα14 NKT cells in IL-12 mediated rejection of tumours. Science. 278:1997;1623-1626.
12. Doherty D.G., Norris S., Madrigal-Estebas L., McEntee G., Traynor O., Hegarty J.E., et al. The human liver contains multiple populations of NK cells, T cells and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2 and Th0 cytokine secretion patterns. J Immunol. 163:1999;2314-2321.
13. Doherty D.G., O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol Rev. 174:2000;5-20.
14. Satoh M., Seki S., Hashimoto W., Ogasawara K., Kobayashi T., Kumagi K., et al. Cytotoxic γδ or αβ T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-2 & IL-12. J Immunol. 157:1996;3886-3892.
15. Kobayashi M., Fitz L., Ryan M., Hewick R.M., Clark S.C., Chan S., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med. 170:1989;827.
16. Wolf S.F., Temple P.A., Kobayashi M., Young D., Dicig M., Lowe L., et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biological effects on T and natural killer cells. J Immunol. 146:(9):1991;3074-3081.
17. Grufman P., Karre K. Innate and adaptive immunity to tumours: IL-12 is required for optimal responses. Eur J Immunol. 30:(4):2000;1088-1093.
18. Gately M.K., Wolitzky A.G., Quinn P.M., Chizzonite R. Regulation of human cytolytic lymphocyte responses by Interleukin 12. Cell Immunol. 143:(1):1992;127-142.
19. Trinchieri G. Interleukin 12: a cytokine produced by antigen presenting cells with immunoregulatory functions in the generation of T helper cells type 1 and cytotoxic lymphocytes. Blood. 84:(12):1994;4008-4027.
20. Trinchieri G., Scott P. Interleukin 12: a proinflammatory cytokine with immunoregulatory functions. Res Immunol. 146:(7-8):1995;423-431.
21. Trinchieri G. Interleukin 12 and its role in the generation of TH1 cells. Immunol Today. 14:(7):1993;335-338.
22. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., et al. Antitumour and antimetastatic activity of Interleukin 12 against murine tumours. J Exp Med. 178:(4):1993;1223-1230.
23. Wigginton J.M., Komschlies K.L., Back T.C., Franco J.L., Brunda M.J., Wiltrout R.H. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst. 88:(1):1996;38-43.
24. Tahara H., Zeh H.J., Storkus W.J., Pappo I., Watkins S.C., Gubler U., et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumour growth and induce antitumour immunity to a murine melanoma in vivo. Cancer Res. 54:(1):1994;182-189.
25. Mu J., Zou J.P., Yamamoto N., Tsutsui T., Tai X.G., Kobayashi M., et al. Administration of recombinant interleukin 12 prevents outgrowth of tumour cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 55:(19):1995;4404-4408.
26. Barajas M., Mazzolini G., Genove G., Bilbao R., Narvaiza I., Schmitz V., et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using Adenovirus coding for Interleukin 12. Hepatology. 33:2001;52-61. 10.1053/jhep.2001.20796.
27. Nasu Y., Bangma C.H., Hull G.W., Lee H.-M, Hu J., Wang J., et al. Adenovirus mediated interleukin 12 gene therapy for prostate cancer; suppression of orthotopic tumour growth and pre-established lung metastases in an orthotopic model. Gene Ther. 6:1999;338-349.
28. +αβ T cells activated by IL-12 as a major effector in inhibition of experimental metastases. J Immunol. 56:1996;3366-3373.
29. Smyth M.J., Taniguchi M., Street S. The anti-tumour activity of IL-12: mechanisms of innate immunity that are model and dose dependant. J Immunol. 165:2000;2665-2670.
30. Gollob J.A. Phase 1 trial of IL-12 in patients with metastatic renal carcinoma or malignant melanoma. Clin Cancer Res. 6:2000;1678-1692.
31. Whiteside T., Heberman R.B. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol. 7:1995;704-710.
32. Kawamura T., Kawachi Y., Moroda T., Weerashinghe A., Seki S., Takada G., et al. Cytotoxic activity against tumour cells mediated by intermediate TCR in the liver and spleen. Immunology. 89:1996;68-75.
33. Ohmori K., Iiai T., Watanabe H., Tanaka T., Miyasaka M., Abo T. Activation of extrathymic T cells in the livers of mice bearing syngenic tumours. Biomed Res. 14:1993;65-79.
34. + αβ T cells with intermediate TCR induced in the livers of mice by IL-12. J Immunol. 154:1995;4333-4340.
35. Dunne J., Lynch S., O'Farrelly C., Todryk S., Hegarty J.E., Feighery C., et al. Selective expansion and partial activation of human NK cells and NK receptor positive T cells by IL-2 and IL-15. J Immunol. 167:(6):2001;3129-3138.
36. Norris S., Doherty D.G., Curry M., McEntee G., Traynor T., Hegarty J.E., et al. Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy. Cancer Immunol Immunother. 52:2003;53-58. 10.1007/S00262-002-0331-1.
37. Curry M.P., Norris S., Golden-Mason L., Doherty D.G., Deignan T., Collins C., et al. Isolation of lymphocytes from normal adult human liver suitable for phenotypic and functional characterisation. J Immunol Methods. 242:(1-2):2000;21-31. 10.1016/S0022-1759(00)00204-0.
38. Golden-Mason L., Kelly A.M., Traynor O., McEntee G., Kelly J., Hegarty J.E., et al. Expression of interleukin 7 (IL-7) mRNA and protein in the normal adult human liver: implications for extrathymic T cell development. Cytokine. 14:(3):2001;143-151. 10.1006/cyto.2001.0852.